of patients presenting with signs and symptoms of threatened preterm labour may be admitted
Clinical evaluation alone, including the measurement of cervical length and dilatation, is not sufficiently predictive of imminent delivery among patients with signs of threatened preterm labour.
Similarly, currently available biomarker tests, such as that which is based on the detection of fetal fibronectin (fFN), have extremely poor positive predictive values for imminent delivery.2
PAMG-1 detection by PartoSure is the single best predictor of imminent spontaneous delivery within 7 days compared to fFN and CL. 3–Nikolova et al., 2015
The PartoSure Test is a rapid, non-invasive strip test for the detection of placental alpha microglobulin-1 (PAMG-1) in patients presenting with signs and symptoms of preterm labour.
- High Positive and Negative Predictive Value
- May be used shortly after vaginal exam
- Speculum examination optional
- Results in 5 minutes or less
- No special equipment or training needed
- Wide gestational age range from 20 to 37 weeks
5. Van Baaren et al. Am J Obstet Gynecol 2013; 209: 436.e1-8.
of patients admitted to the hospital for threatened preterm labour (PTL) do not deliver within the next 7 days.4
Average charges for threatened preterm labor management can cost up to $20.3K.5
5. Lucovnik et al., Am J Obstet Gynecol. 2013 Sep;209(3):217.e1-3.
- Reducing the length of stay of high risk patients
- Decreasing unnecessary admissions and acute interventions
- Minimizing unnecessary patient transfers
cervical length is equivocal
The PartoSure test is most useful in cases where cervical length is between 15 and 30 mm where the predictive value of cervical length is lowest. While a cervical length-cutoff of 25 mm is often utilized, up to 1 in 8 women with a cervical length between 25-30 mm will deliver within the next 7 days.6
The novel bedside PAMG-1 test has a higher positive predictive value compared to other commercially available bedside tests for preterm birth such as fetal fibronectin or IGFBP-1. 7
The PartoSure Test is intended to be used as an aid to rapidly assess the risk of preterm delivery in ≤7 or ≤14 days from the time of cervicovaginal sample collection in pregnant women with signs and symptoms of early preterm labour, intact amniotic membranes and minimal cervical dilatation (≤3 cm), sampled between 20 weeks, 0 days and 36 weeks, 6 days gestation.
© 2017 PartoSure Test. © 2017 Parsagen Diagnostics, Inc. The PartoSure Test is CE marked and is currently investigational use only in the United States.